Quick Answer
ImageneBio, Inc. reported Total Revenue of $800.0 thousand for fiscal year 2025.
ImageneBio, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $800.0K -77.1% |
$3.50M -61.8% |
$9.16M -41.3% |
$15.62M -49.6% |
$30.98M +237.0% |
$9.19M |
| Revenue (ASC 606) | $800.0K -77.1% |
$3.50M -61.8% |
$9.16M -41.3% |
$15.62M -49.6% |
$30.98M +237.0% |
$9.19M |
| Net Income | -$45.35M -24.0% |
-$36.57M +46.4% |
-$68.17M +0.9% |
-$68.77M -101.6% |
-$34.12M +22.9% |
-$44.26M |
| Diluted EPS | -$9.64 +56.4% |
-$22.10 -1255.8% |
-$1.63 +14.2% |
-$1.90 -55.7% |
-$1.22 | — |
| Total Assets | $152.98M +860.8% |
$15.92M -91.7% |
$192.09M +11.5% |
$172.26M -30.5% |
$247.88M +47.2% |
$168.40M |
| Cash and Equivalents | $94.53M +680.1% |
$12.12M -89.9% |
$119.89M +100.1% |
$59.92M -74.2% |
$232.22M +42.9% |
$162.49M |
| Stockholders Equity | $133.14M +182.9% |
-$160.56M -27.3% |
-$126.11M -185.8% |
$146.97M -29.3% |
$207.88M +305.7% |
-$101.05M -64.4% |
| R&D Expense | $28.52M -11.2% |
$32.11M -46.2% |
$59.65M -7.3% |
$64.32M +36.5% |
$47.11M +5.0% |
$44.85M |
| Operating Income | -$48.45M -30.9% |
-$37.00M +50.9% |
-$75.42M -6.4% |
-$70.90M -107.7% |
-$34.14M +23.3% |
-$44.52M |
| Shares Outstanding | — | 48.26M +0.0% |
48.26M +33.1% |
36.26M +0.8% |
35.98M +1061.6% |
3.10M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2024 | $3.50M | +195.4% | +195.4% |
| Revenue (ASC 606) | September 30, 2024 | $3.50M | +195.4% | +195.4% |
| Net Income | September 30, 2025 | -$24.78M | -678.5% | -226.7% |
| Diluted EPS | September 30, 2025 | -$2.91 | -12.8% | -4750.0% |
| Total Assets | September 30, 2025 | $160.88M | +8.0% | +27.5% |
| Cash and Equivalents | September 30, 2025 | $103.16M | +128.3% | +77.0% |
| Stockholders Equity | September 30, 2025 | $139.83M | +191.5% | +177.5% |
| R&D Expense | September 30, 2025 | $15.56M | +300.5% | +286.5% |
| Operating Income | September 30, 2025 | -$26.59M | -1206.2% | -203.9% |
| Shares Outstanding | June 30, 2025 | 48.26M | +0.0% | +0.0% |
- ImageneBio, Inc. reported Total Revenue of $800.0 thousand for fiscal year 2025.
- ImageneBio, Inc. showed a decrease of -77.1% in Total Revenue compared to the prior fiscal year.
- ImageneBio, Inc. reported Revenue (ASC 606) of $800.0 thousand for fiscal year 2025.
- ImageneBio, Inc. showed a decrease of -77.1% in Revenue (ASC 606) compared to the prior fiscal year.
- ImageneBio, Inc. reported Net Income of -$45.35 million for fiscal year 2025.
- ImageneBio, Inc. showed a decrease of -24.0% in Net Income compared to the prior fiscal year.
- ImageneBio, Inc. reported Diluted EPS of $9.64 per share (loss) for fiscal year 2025.
- ImageneBio, Inc. showed an increase of +56.4% in Diluted EPS compared to the prior fiscal year.
- ImageneBio, Inc. reported Total Assets of $152.98 million for fiscal year 2025.
- ImageneBio, Inc. showed an increase of +860.8% in Total Assets compared to the prior fiscal year.
- ImageneBio, Inc. reported Cash and Equivalents of $94.53 million for fiscal year 2025.
- ImageneBio, Inc. showed an increase of +680.1% in Cash and Equivalents compared to the prior fiscal year.
- ImageneBio, Inc. reported Stockholders Equity of $133.14 million for fiscal year 2025.
- ImageneBio, Inc. showed an increase of +182.9% in Stockholders Equity compared to the prior fiscal year.
- ImageneBio, Inc. reported R&D Expense of $28.52 million for fiscal year 2025.
- ImageneBio, Inc. showed a decrease of -11.2% in R&D Expense compared to the prior fiscal year.
- ImageneBio, Inc. reported Operating Income of -$48.45 million for fiscal year 2025.
- ImageneBio, Inc. showed a decrease of -30.9% in Operating Income compared to the prior fiscal year.
- ImageneBio, Inc. reported Shares Outstanding of 48.26 million shares for fiscal year 2024.
- ImageneBio, Inc. showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: